STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 167922

TO: David Lukton
Location: REM/3B75/3C18
Art Unit: 1654
Oct 10, 2005

Case Serial Number: 09/963927

From: P. Sheppard
Location: Remsen Building
Phone: (571) 272-2529

sheppard@uspto.gov

Search Notes

THIS PAGE BLANK (USPTO)

ACCESS DB # 169952

SEARCH REQUEST FORM
(STIC)

Requestor's Name: David Lukton Examiner number: 71263 Date: 10/5/05

Art Unit: 1654 Phone number: 571-272-0952 Serial Number: 09-963927

Mail Box: 3-C-18 Examiner Rm: 3-B-75 Results format: paper

****

Title: Hydroxy Acid Integrin Antagonists

Applicants: ROGERS, THOMAS; PENNING, THOMAS D.; JIANG, LAN; DEVADAS, BALEKUDRU; RUMINISKI, PETER; VANCAMP, JENNIFER; YUAN, CHESTER

Earliest Priority Date: 9/28/00

* * * *



R^5 = anything

R^6 = anything

R^8 = anything

R^9 = anything

Y is an oxygen atom, or else "Y" is >N-R^1, wherein R^1 can be anything

****

STAFF USE ONLY

Searcher: _____

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: _____

Searcher Prep & Review Time: _____

Online Time: _____

Type of Search

_____ NA Sequence (#)

_____ AA Sequence (#)

_____ Structure (#)

_____ Bibliographic

_____ Litigation

_____ Fulltext

_____ Other

Vendors and cost where applicable

_____ STN _____ Dialog

_____ Questel/Orbit _____ Lexis/Nexis

_____ Westlaw _____ WWW/Internet

____ In-house sequence systems

__ Commercial ___ Oligomer ____ Score/Length

__ Interference ___ SPDI ____ Encode/Transl

_____ Other (specify)

THIS PAGE BLANK (USPTO)

```
=> d his ful

     (FILE 'HOME' ENTERED AT 18:12:03 ON 11 OCT 2005)

     FILE 'REGISTRY' ENTERED AT 18:12:11 ON 11 OCT 2005
L1             STR
L2           3 SEA SSS SAM L1
L3          78 SEA SSS FUL L1

     FILE 'HCAPLUS' ENTERED AT 18:16:05 ON 11 OCT 2005
L4           5 SEA ABB=ON  PLU=ON  L3
               D STAT QUE
               D IBIB ABS HITSTR L4 1-5


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   10 OCT 2005  HIGHEST RN 864908-12-3
     DICTIONARY FILE UPDATES:  10 OCT 2005  HIGHEST RN 864908-12-3

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
     for details.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/ONLINE/UG/regprops.html

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     the American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
```

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Oct 2005 VOL 143 ISS 16
FILE LAST UPDATED: 10 Oct 2005 (20051010/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 18:16:05 ON 11 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 11 Oct 2005 VOL 143 ISS 16
FILE LAST UPDATED: 10 Oct 2005 (20051010/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d stat que
L1 STR



VAR G1=O/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE
L3 78 SEA FILE=REGISTRY SSS FUL L1
L4 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L3

=>
=> d ibib abs hitstr l4 1-5

L4 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:256240 HCAPLUS
DOCUMENT NUMBER: 136:279118
TITLE: Preparation and use of amido-hydroxy-carboxylic acid integrin antagonists
INVENTOR(S): Rogers, Thomas; Penning, Thomas D.; Jiang, Lan; Devadas, Balekudru; Ruminiski, Peter; Chester, Yuan; Vancamp, Jennifer
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002026717	A2	20020404	WO 2001-US30189		20010927
WO 2002026717	C1	20021227			
WO 2002026717	A3	20020912			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2002072500	A1	20020613	US 2001-963927		20010926
CA 2423464	AA	20020404	CA 2001-2423464		20010927
AU 2001093131	A5	20020408	AU 2001-93131		20010927
EP 1322623	A2	20030702	EP 2001-973568		20010927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004509950	T2	20040402	JP 2002-531101		20010927
US 2004024062	A1	20040205	US 2003-381825		20030327
PRIORITY APPLN. INFO.:			US 2000-235616P	P	20000927
			US 2000-241656P	P	20001010
			WO 2001-US30189	W	20010927

OTHER SOURCE(S): MARPAT 136:279118
GI



I



II

AB Title compds. I [X = NHC:YNR8R9, NHC:NR1NR8R9, etc.; Y = NR1, O, S; A = N, C; R1 = H, alkyl, aryl, hydroxy, alkoxy, cyano, nitro, amino, alkenyl, alkynyl, amido, etc. or R1 taken together with R8 forms a 4-12 membered heterocycle; R8 (when not taken together with R1), R9 = H, alk(en/yn)yl, aralkyl, amino, alkylamino, hydroxy, alkoxy, arylamino, amido, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxy, aryloxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl, acyloxymethoxycarbonyl, etc. or NR8 and R9 taken together form a 4-12 membered heterocycle; R2-4 = H, alkyl, hydroxy, alkoxy, aryloxy, halogen, haloalkyl, haloalkoxy, nitro, amino, alkylamino, acylamino, dialkylamino, cyano, alkylthio, etc.; R5-7 = H, alk(en/yn)yl, aryl, carboxy derivs., haloalkyl, cycloalkyl, monocyclic heterocycles, monocyclic heterocycles optionally substituted with alkyl, halogen, haloalkyl, cyano, hydroxy, aryl, fused aryl, nitro, alkoxy, aryloxy, alkylsulfonyl, arylsulfonyl, sulfonamide, thio, alkylthio, carboxy derivs., amino, amido, etc.] were prepared For instance, (4S)-4-aminodihydro-2(3H)furanone hydrochloride (preparation given) was reacted with Boc-Gly-OSu (DMF, NMM, 0°C, 18 h) and the product deprotected with 4N HCl. The intermediate amine was condensed with the corresponding carboxylic acid (prior art, DMF, CH2Cl2, DCC, NMM, 18 h) to give intermediate lactone II isolated as the TFA salt. The desired hydroxy acid was obtained by hydrolysis and isolation at a final pH of approx. 8. Example compds. had IC50 = 0.1 nM - 100 nM for the αvβ3 integrin and IC50 < 50μM for the αvβ5 integrin. I are useful for the treatment of tumor metastasis, solid tumor growth, macular degeneration, etc.

IT **406682-29-9P 406682-30-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation and use of amido-hydroxy-carboxylic acid integrin antagonists)

RN 406682-29-9 HCAPLUS

CN Butanoic acid, 3-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-4-hydroxy-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 406682-30-2 HCAPLUS
CN Butanoic acid, 3-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-4-hydroxy-, (3S)-, trifluoroacetate (2:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 406682-29-9
CMF C15 H18 F3 N5 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:44410 HCAPLUS
DOCUMENT NUMBER: 136:259122
TITLE: Comparative Study of the Active Site Caging of Serine Proteases: Thrombin and Factor Xa

AUTHOR(S): Thuring, Jan Willem; Li, Hui; Porter, Ned A.
CORPORATE SOURCE: Department of Chemistry, Duke University, Durham, NC, 27708, USA
SOURCE: Biochemistry (2002), 41(6), 2002-2013
CODEN: BICHAW; ISSN: 0006-2960
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:259122

AB Bovine thrombin and human factor Xa were acylated at their active site selectively with inhibitors derived from the parent compound 4-guanidinophenyl (E)-4-diethylamino-2-hydroxy-α-methylcinnamate hydrochloride, 1b. Peptidyl side chains were attached to the phenol ring via amide connection, which served as a recognition motif in inhibiting different serine proteases. Upon irradiation with 366 nm light, the trans-cinnamate attached to the active-site serine isomerizes to the cis isomer which then rapidly lactonizes to release the free enzyme. The peptidyl side chain sequences specific for each serine protease were revealed via constructing and screening a library of homologous compds. This methodol. may be applied to other proteases. One application based on enzyme-specific, photoactivatable inhibitors is to isolate a designated active protease from a mixture of several proteases. Thus, a cinnamate inhibitor with a biotin moiety, 1d, was synthesized. A solution of enzyme-specific, biotinylated inhibitor was added into a mixture of proteases containing a target enzyme. The target enzyme was acylated at the active site and subsequently bore a biotin tail. An avidin column was used to sep. the biotinylated enzyme from the unmodified ones, by a strong binding between biotin and avidin. After a brief irradiation on the avidin column, the retained enzymes were released from the biotin tag and eluted off the column. To demonstrate the idea, thrombin and factor Xa have been separated from each other by this strategy.

IT **405074-68-2 405074-76-2 405074-88-6**
405074-98-8 405075-06-1 405075-14-1
405075-22-1 405075-30-1 405075-38-9
405075-46-9 405075-54-9 405075-61-8
405075-69-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(library of photoactivatable peptide-substituted cinnamate inhibitors permits comparative study of active site caging in thrombin and factor Xa)

RN 405074-68-2 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-α-aspartyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247106-31-6
CMF C30 H37 N7 O10

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 405074-76-2 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-alanyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247106-23-6
CMF C29 H37 N7 O8

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 405074-88-6 HCAPLUS
CN L-α-Asparagine, N2-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-arginyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247107-19-3
CMF C32 H44 N10 O8

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 405074-98-8 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-3-cyclohexyl-L-alanyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247107-27-3
CMF C35 H47 N7 O8

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 405075-06-1 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-α-glutamyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247106-39-4
CMF C31 H39 N7 O10

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 405075-14-1 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]glycyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247106-47-4
CMF C28 H35 N7 O8

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 405075-22-1 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-isoleucyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247106-55-4
CMF C32 H43 N7 O8

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 405075-30-1 HCAPLUS
CN L-α-Asparagine, N2-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-

lysyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247106-63-4
CMF C32 H44 N8 O8

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 405075-38-9 HCAPLUS
CN L-α-Asparagine, N2-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-ornithyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247106-71-4
CMF C31 H42 N8 O8

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 405075-46-9 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-phenylalanyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247106-79-2
CMF C35 H41 N7 O8

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 405075-54-9 HCAPLUS
CN L-α-Asparagine, (2S)-N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-2-phenylglycyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247106-87-2
CMF C34 H39 N7 O8

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 405075-61-8 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-tryptophyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247107-03-5
CMF C37 H42 N8 O8

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 405075-69-6 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-tyrosyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247107-11-5
CMF C35 H41 N7 O9

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:659421 HCAPLUS
DOCUMENT NUMBER: 131:295583
TITLE: Dual avb3 and metastasis-associated receptor ligands
INVENTOR(S): Tjoeng, Foe S.; Fok, Kam F.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951638	A1	19991014	WO 1999-US4295	19990407

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2325342	AA	19991014	CA 1999-2325342	19990407
AU 9935453	A1	19991025	AU 1999-35453	19990407
EP 1070085	A1	20010124	EP 1999-917301	19990407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002510709	T2	20020409	JP 2000-542359	19990407
PRIORITY APPLN. INFO.:			US 1998-81074P	P 19980408
			WO 1999-US4295	W 19990407

OTHER SOURCE(S): MARPAT 131:295583

AB The present invention relates to pharmaceutical compds. which are dual avb3 receptor/metastasis-associated receptor ligands. The use of these dual ligands alone or in conjunction with other agents in pharmaceutical compns., and in methods for treating conditions mediated by avb3 for the treatment of cancer and other angiogenic diseases, such as diabetic retinopathy, arthritis, hemangiomas, and psoriasis, are also disclosed.

IT **246135-47-7P 246135-52-4P 246135-53-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(dual Avb3 and metastasis-associated receptor ligands in relation to angiogenesis inhibitor activity and treatment of cancer and other diseases)

RN 246135-47-7 HCAPLUS

CN L-Serinamide, N-[3-[[[(phenylmethyl)amino]carbonyl]amino]benzoyl]glycyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246135-52-4 HCAPLUS

CN L-Serinamide, N-[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]glycyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246135-53-5 HCAPLUS

CN L-Serinamide, N-[3-[(aminoiminomethyl)amino]benzoyl]glycyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **246135-81-9DP**, conjugates with interferon α
246135-82-0DP, conjugates with interferon α
246135-83-1DP, conjugates with interferon α
246135-84-2DP, conjugates with interferon α
246135-85-3DP, conjugates with interferon α
246135-86-4DP, conjugates with interferon α
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(dual Avb3 and metastasis-associated receptor ligands in relation to angiogenesis inhibitor activity and treatment of cancer and other diseases)

RN 246135-81-9 HCAPLUS

CN L-Alanine, N-[3-[[[(phenylmethyl)amino]carbonyl]amino]benzoyl]glycyl-L-α-aspartylthio-, 3-S-(2-carboxyethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 246135-82-0 HCAPLUS
CN L-Serine, N-[3-[[[(phenylmethyl)amino]carbonyl]amino]benzoyl]glycyl-L-α-aspartylthio-, 3-S-(2-carboxyethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 246135-83-1 HCAPLUS
CN L-Alanine, N-[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]glycyl-L-α-aspartylthio-, 3-S-(2-carboxyethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246135-84-2 HCAPLUS
CN L-Serine, N-[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]glycyl-L-α-aspartylthio-, 3-S-(2-carboxyethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246135-85-3 HCAPLUS
CN L-Alanine, N-[3-[(aminoiminomethyl)amino]benzoyl]glycyl-L-α-aspartylthio-, 3-S-(2-carboxyethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 246135-86-4 HCAPLUS
CN L-Serine, N-[3-[(aminoiminomethyl)amino]benzoyl]glycyl-L-α-aspartylthio-, 3-S-(2-carboxyethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:484855 HCAPLUS
DOCUMENT NUMBER: 131:296952
TITLE: Selective Inhibition, Separation, and Purification of Serine Proteases: A Strategy Based on a Photoremovable Inhibitor

AUTHOR(S): Porter, Ned. A.; Thuring, Jan Willem; Li, Hui
CORPORATE SOURCE: Department of Chemistry, Duke University, Durham, NC, 27708, USA
SOURCE: Journal of the American Chemical Society (1999), 121(33), 7716-7717
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 131:296952

AB Controlling biol. activity with light has become an important strategy for the study of processes as diverse as the activity of neurotransmitters and the coagulation of blood. In the past decade our own efforts have involved the successful use of a strategy to modify the catalytic residue of serine proteases with a photolabile moiety, effectively modifying the enzyme with a photoremovable cage. Caged enzymes generated from proteases of the coagulation cascade can be used to initiate plasma coagulation in vitro and in vivo. The potential for therapeutic and diagnostic applications of such strategies has, however, been largely untapped as has its utility in approaching more general chemical and biochem. problems. We report here a strategy that permits the selective inhibition, separation, and reactivation of two of the coagulation enzymes, thrombin and factor Xa. These studies demonstrate that specific proteases in a mixture of enzymes can be targeted, isolated, and regenerated in their fully active form by means of generating caged enzymes selectively.

IT **247106-23-6P 247106-31-6P 247106-39-4P**
247106-47-4P 247106-55-4P 247106-63-4P
247106-71-4P 247106-79-2P 247106-87-2P
247107-03-5P 247107-11-5P 247107-19-3P
247107-27-3P
RL: BPR (Biological process); BSU (Biological study, unclassified); NUU (Other use, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(selective inhibition, separation, and purification of serine proteases using a
strategy based on a photoremovable inhibitor)

RN 247106-23-6 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 247106-31-6 HCAPLUS

CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 247106-39-4 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 247106-47-4 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 247106-55-4 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 247106-63-4 HCAPLUS
CN L-α-Asparagine, N2-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 247106-71-4 HCAPLUS
CN L-α-Asparagine, N2-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 247106-79-2 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 247106-87-2 HCAPLUS
CN L-α-Asparagine, (2S)-N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 247107-03-5 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 247107-11-5 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 247107-19-3 HCAPLUS
CN L-α-Asparagine, N2-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 247107-27-3 HCAPLUS
CN L-α-Asparagine, N-[5-[(aminoiminomethyl)amino]-2-[[(2E)-3-[4-(diethylamino)-2-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]oxy]benzoyl]-3-cyclohexyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:290093 HCAPLUS
DOCUMENT NUMBER: 126:264011
TITLE: Preparation of meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
INVENTOR(S): Ruminski, Peter Gerrard; Clare, Michael; Collins, Paul Waddell; Desai, Bipinchandra Nanubhai; Lindmark, Richard John; Rico, Joseph Gerace; Rogers, Thomas Edward; Russell, Mark Andrew; et al.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA; Ruminski, Peter Gerrard;

	Clare, Michael; Collins, Paul Waddell; Desai, Bipinchandra Nanubhai; Lindmark, Richard, John
SOURCE:	PCT Int. Appl., 930 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9708145	A1	19970306	WO 1996-US13500	19960827
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
CA 2230209	AA	19970306	CA 1996-2230209	19960827
AU 9671039	A1	19970319	AU 1996-71039	19960827
AU 702487	B2	19990225		
EP 850221	A1	19980701	EP 1996-932142	19960827
EP 850221	B1	20010718		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1201454	A	19981209	CN 1996-197911	19960827
CN 1085980	B	20020605		
BR 9610422	A	19990713	BR 1996-10422	19960827
JP 11510814	T2	19990921	JP 1996-510397	19960827
IL 123164	A1	20010319	IL 1996-123164	19960827
AT 203234	E	20010815	AT 1996-932142	19960827
PT 850221	T	20011130	PT 1996-932142	19960827
ES 2161373	T3	20011201	ES 1996-932142	19960827
RU 2196769	C2	20030120	RU 1998-105408	19960827
RO 118290	B1	20030430	RO 2001-1069	19960827
RO 118289	B1	20030430	RO 1998-500	19960827
PL 186370	B1	20031231	PL 1996-325312	19960827
CZ 293323	B6	20040414	CZ 1998-341	19960827
ZA 9607379	A	19980330	ZA 1996-7379	19960830
NO 9800817	A	19980424	NO 1998-817	19980226
NO 311671	B1	20020102		
HK 1021532	A1	20020208	HK 1998-114666	19981228
GR 3036751	T3	20011231	GR 2001-401608	20010928
PRIORITY APPLN. INFO.:			US 1995-3277P P	19950830
			WO 1996-US13500 W	19960827

OTHER SOURCE(S):	MARPAT 126:264011
GI	



I



II

AB The title compds. I [A = (un)substituted ureido, guanidino, etc. (generic structures given); Z1 = H, alkyl, OH, alkoxy, halo, (di)(alkyl)amino, aryl, etc.; V = NR6; R6 = H, alkyl, etc.; or YR6 forms a 4- to 12-membered mono-N-containing ring; Y, Y3, Z, Z3 = H, alkyl, aryl, cycloalkyl; or YZ or Y3Z3 form cycloalkyl; n = 1-3; t = 0-2; p = 0-3; R = XR3; X = O, S, NH, etc.; R3 = H, alkyl, etc.; R1 = H, alkyl, alkenyl, etc.; R11 = H, alkyl, aralkyl, etc.] are prepared For example, m-nitrohippuric acid was subjected to a sequence of (1) amidation with Et 3-amino-3-(3-pyridyl)propanoate-2HCl; (2) hydrogenation of the nitro group; (3) reaction of the formed amine with benzyl isocyanate; and (4) alkaline saponification of the ester, to give
title compound II, isolated as the CF3CO2H or HCl salt. In an in vitro assay for antagonism of human vitronectin receptor (αVβ3), the title compound II.HCl bound with an IC50 of 0.86 nM.

IT **188805-63-2P 188805-80-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of meta-guanidino, -ureido, -thioureido, or -azacyclic-amino benzoic acid derivs. as integrin antagonists)

RN 188805-63-2 HCAPLUS

CN Butanoic acid, 3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-hydroxy-, (S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 188805-08-5
CMF C14 H19 N5 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 188805-80-3 HCAPLUS
CN Butanoic acid, 4-[(2-aminobenzoyl)oxy]-3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **188805-08-5P 188805-12-1P 188805-13-2P**
188805-17-6P 188805-18-7P 188811-53-2P
188811-54-3P 188811-55-4P 188811-56-5P
188811-57-6P 188811-58-7P 188811-59-8P
188811-60-1P 188811-61-2P 188811-62-3P
188811-63-4P 188811-64-5P 188811-66-7P
188811-67-8P 188811-68-9P 188811-69-0P
188811-70-3P 188811-85-0P 188811-86-1P
188811-87-2P 188811-88-3P 188811-89-4P
188811-90-7P 188811-91-8P 188811-92-9P
188811-93-0P 188811-94-1P 188811-95-2P
188811-96-3P 188811-97-4P 188811-98-5P
188811-99-6P 188812-00-2P 188812-01-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of meta-guanidino, -ureido, -thioureido, or -azacyclic-amino benzoic acid derivs. as integrin antagonists)

RN 188805-08-5 HCAPLUS
CN Butanoic acid, 3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-hydroxy-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 188805-12-1 HCAPLUS
CN α-Asparagine, N-[3-[(aminoiminomethyl)amino]benzoyl]glycyl-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 188805-13-2 HCAPLUS
CN α-Asparagine, N-[3-[(aminoiminomethyl)amino]benzoyl]glycyl-N-(2-hydroxyethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 188805-12-1
CMF C16 H22 N6 O6



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 188805-17-6 HCAPLUS
CN Butanoic acid, 4-[(2-aminobenzoyl)oxy]-3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 188805-18-7 HCAPLUS
CN Butanoic acid, 4-[(2-aminobenzoyl)oxy]-3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-, (S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 188805-17-6
CMF C21 H24 N6 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 188811-53-2 HCAPLUS

CN Butanoic acid, 3-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 188811-54-3 HCAPLUS
CN Hexanoic acid, 3-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-5,5,6,6,6-pentafluoro-4-oxo- (9CI) (CA INDEX NAME)



RN 188811-55-4 HCAPLUS
CN Benzenebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-γ-hydroxy- (9CI) (CA INDEX NAME)



RN 188811-56-5 HCAPLUS
CN Benzenebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-4-fluoro-γ-hydroxy- (9CI) (CA INDEX NAME)



RN 188811-57-6 HCAPLUS
CN Benzenebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-4-bromo-γ-hydroxy- (9CI) (CA INDEX NAME)



RN 188811-58-7 HCAPLUS
CN 5-Hexynoic acid, 3-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 188811-59-8 HCAPLUS
CN 6-Heptenoic acid, 3-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 188811-60-1 HCAPLUS
CN Cyclopentanebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-γ-hydroxy- (9CI) (CA INDEX NAME)



RN 188811-61-2 HCAPLUS
CN 5-Hexynoic acid, 3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-hydroxy-6-phenyl- (9CI) (CA INDEX NAME)



RN 188811-62-3 HCAPLUS
CN Pentonic acid, 3-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-2,3,5-trideoxy- (9CI) (CA INDEX NAME)



RN 188811-63-4 HCAPLUS
CN Hexanoic acid, 3-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-4-hydroxy-5-methyl- (9CI) (CA INDEX NAME)



RN 188811-64-5 HCAPLUS
CN 1,3-Benzodioxole-5-butanoic acid, β-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-γ-hydroxy- (9CI) (CA INDEX NAME)



RN 188811-66-7 HCAPLUS
CN Benzenebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-γ-oxo- (9CI) (CA INDEX NAME)



RN 188811-67-8 HCAPLUS
CN Benzenebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-4-chloro-γ-oxo- (9CI) (CA INDEX NAME)



RN 188811-68-9 HCAPLUS
CN Benzenebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-4-bromo-γ-oxo- (9CI) (CA INDEX NAME)



RN 188811-69-0 HCAPLUS
CN 1,3-Benzodioxole-5-butanoic acid, β-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-γ-oxo- (9CI) (CA INDEX NAME)



RN 188811-70-3 HCAPLUS
CN Benzenebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-4-methyl-γ-oxo- (9CI) (CA INDEX NAME)



RN 188811-85-0 HCAPLUS
CN Hexanoic acid, 3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-5,5,6,6,6-pentafluoro-4-oxo- (9CI) (CA INDEX NAME)



RN 188811-86-1 HCAPLUS
CN Benzenebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-chloro-γ-hydroxy- (9CI) (CA INDEX NAME)



RN 188811-87-2 HCAPLUS
CN Benzenebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-bromo-γ-hydroxy- (9CI) (CA INDEX NAME)



RN 188811-88-3 HCAPLUS
CN 3-Cyclopentene-1-butanoic acid, β-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-γ-hydroxy- (9CI) (CA INDEX NAME)



RN 188811-89-4 HCAPLUS
CN Hexanoic acid, 3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-hydroxy-5-methyl- (9CI) (CA INDEX NAME)



RN 188811-90-7 HCAPLUS
CN 5-Hexenoic acid, 3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 188811-91-8 HCAPLUS
CN 6-Heptenoic acid, 3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 188811-92-9 HCAPLUS
CN Pentonic acid, 3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-2,3,5-trideoxy- (9CI) (CA INDEX NAME)



RN 188811-93-0 HCAPLUS
CN Benzenebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-γ-oxo- (9CI) (CA INDEX NAME)



RN 188811-94-1 HCAPLUS
CN Benzenebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-chloro-γ-oxo- (9CI) (CA INDEX NAME)



RN 188811-95-2 HCAPLUS
CN Benzenebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-bromo-γ-oxo- (9CI) (CA INDEX NAME)



RN 188811-96-3 HCAPLUS
CN 1,3-Benzodioxole-5-butanoic acid, β-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-γ-oxo- (9CI) (CA INDEX NAME)



RN 188811-97-4 HCAPLUS
CN Benzenebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-fluoro-γ-oxo- (9CI) (CA INDEX NAME)



RN 188811-98-5 HCAPLUS
CN Benzenebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-methyl-γ-oxo- (9CI) (CA INDEX NAME)



RN 188811-99-6 HCAPLUS
CN Cyclopentanebutanoic acid, β-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-γ-oxo- (9CI) (CA INDEX NAME)



RN 188812-00-2 HCAPLUS
CN 5-Hexynoic acid, 3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 188812-01-3 HCAPLUS
CN 5-Hexenoic acid, 3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



=>

THIS PAGE BLANK (USPTO)